Artiva Biotherapeutics
Biotechnology, 5505 Morehouse Dr, San Diego, California, 92121, United States, 51-200 Employees
Phone Number: 51********
Who is ARTIVA BIOTHERAPEUTICS
Artiva Biotherapeutics is an immunotherapy company with the ability to produce off-the-shelf, allogeneic NK cell therapies at a massive scale. Our mission is to develop effective, safe an...
Read More
-
Headquarters: 5505 Morehouse Dr, San Diego, California, 92121, United States
-
Date Founded: 2019
-
Employees: 51-200
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
-
CEO:
Fred Aslan
Email
Phone
Industry: Biotechnology
SIC Code: 8731
Does something look wrong? Fix it. | View contact records from ARTIVA BIOTHERAPEUTICS
Artiva Biotherapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Artiva Biotherapeutics
Answer: Artiva Biotherapeutics's headquarters are located at 5505 Morehouse Dr, San Diego, California, 92121, United States
Answer: Artiva Biotherapeutics's phone number is 51********
Answer: Artiva Biotherapeutics's official website is https://artivabio.com
Answer: Artiva Biotherapeutics's revenue is $10 Million to $25 Million
Answer: Artiva Biotherapeutics's SIC: 8731
Answer: Artiva Biotherapeutics has 51-200 employees
Answer: Artiva Biotherapeutics is in Biotechnology
Answer: Artiva Biotherapeutics contact info: Phone number: 51******** Website: https://artivabio.com
Answer: Artiva Biotherapeutics is an immunotherapy company with the ability to produce off-the-shelf, allogeneic NK cell therapies at a massive scale. Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our lead program, AlloNK, is an allogeneic, non-genetically modified NK cell therapy candidate designed to enhance the activity of monoclonal antibodies or NK cell engagers. AlloNK is currently in clinical trials in combination with rituximab for treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis and for treatment of Non-Hodgkin Lymphoma, as well as in combination with Affimeds innate cell engager AFM13 for the treatment of patients with relapsed/refractory CD30-positive lymphomas.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month